Is there a retatrutide dosing guide? Why no approved dose exists

TL;DR

• There is no approved retatrutide dosing guide in any jurisdiction - the compound is investigational, so no approved label exists for one to be derived from.
• The guides that surface in search are paraphrased trial protocols, forum anecdote, or invented - none of them is prescribing information, whatever the table looks like.
• A protocol figure is inseparable from its apparatus - screening, a characterised drug product, an accountable investigator, structured monitoring and pre-registered endpoints, none of which travel with the number.
• Concentration cannot be assumed outside the regulated supply chain - on 3 August 2026 a US peptide seller's owner was sentenced to 70 months after admitting he forged certificates of analysis.
• "Research Use Only" is not a legal shield - the FDA's 31 March 2026 warning letter covering retatrutide and tirzepatide applied the intended-use doctrine at 21 CFR 201.128, and seven more letters followed in April 2026.
• Lilly plans a BLA in Q1 2027, with active litigation over whether retatrutide is regulated as a biologic or a drug - and a planned submission is not an approval.

Educational content, not medical advice. This is an evidence explainer, not a treatment recommendation.

---

The direct answer

There is no approved retatrutide dosing guide, anywhere, in any jurisdiction, because there is no approved retatrutide.

That sentence is doing more work than it appears to. It is not a statement about whether the drug works - the Phase 3 data are genuinely striking, and we cover them below and in the retatrutide evidence review. It is a statement about what documents exist. A dosing guide, in the sense that a clinician or a pharmacist means it, is a derivative of an approved label. The label is the artefact that a regulator has reviewed, negotiated and signed off. Remove the label and the guide has nothing underneath it.

So when a page presents itself as a retatrutide dosing guide, there are only three things it can be. It can be a paraphrase of a clinical trial protocol, which is a different kind of document with different assumptions built into it. It can be a summary of what people report doing to each other in forums, which is anecdote with the confidence of a table. Or it can be fabricated. In practice most are some blend of the first two, presented with the visual grammar of the third thing they are not - prescribing information.

We do not publish figures for retatrutide. Not paraphrased, not "for illustration", not inside a quotation from somewhere else. That is a standing editorial position, and the rest of this article is the reasoning behind it rather than an apology for it.

What "investigational" actually means

"Investigational" is a precise regulatory term, and it is worth separating from the two things people usually hear when they read it.

It does not mean the drug is unstudied. Retatrutide has been through a substantial clinical programme, and the Phase 3 readouts described below are registrational-quality evidence produced at real scale. It also does not mean the drug is dangerous in some special way that other drugs are not. Every approved medicine you have ever taken was investigational first.

What it means is narrow and specific: no marketing application for the drug has been approved by the FDA. Legally, the drug may be used in the United States only within an authorised clinical investigation or a formal expanded-access arrangement, under an Investigational New Drug framework, with an investigator responsible for the participant. There is no approved prescribing information. There is no approved indication. There is no approved population. There is no approved dosing section, because a dosing section is part of a label, and the label is what approval produces.

This distinction is the one the guides quietly erase. They inherit the authority of the trial programme - real trials, real endpoints, real journal coverage - and attach it to a document type that the trial programme has not produced. The science is genuine. The prescribing information does not exist yet. Both of those things are true at once, and holding them together is the whole literacy skill this page is trying to transfer.

What an FDA-approved label is, and what it guarantees

It is easy to think of a label as a formality - the leaflet nobody reads. It is closer to a contract.

An approved label is the product of a regulator examining the manufacturer's full dataset and then negotiating, clause by clause, what may be claimed and under what conditions. Once approved, it carries a set of guarantees that no other document about a drug can carry:

• A defined indication and population. Who the drug was studied in and who it is approved for - which is often narrower than the enthusiasm around it.
• Contraindications and warnings derived from the actual safety database, including boxed warnings where the agency judged them necessary.
• Monitoring expectations - what should be checked, and when.
• Interaction information assessed against the drug's real pharmacology.
• A defined product. This is the part people skip. The label describes a specific formulation, made to a specific standard, at a specific stated strength, manufactured under inspected conditions. The dosing section is only meaningful because the product it refers to is defined.
• Legal accountability. A manufacturer is answerable for the label. Nobody is answerable for a forum post.

A dosing guide with no label behind it is missing every one of those. It has the shape of prescribing information with the substance removed - and the shape is what persuades. For the wider framework of what regulatory review does and does not certify, see what FDA accelerated approval actually means.

A trial protocol is not prescribing information

Most of the numbers circulating for retatrutide ultimately trace back to published clinical trial protocols. Those protocols are public documents, and this is the point most often used to argue that republishing them is harmless. It is worth taking that argument seriously, because it is half right.

A trial protocol is not a prescription. It is a description of a controlled experiment, and every figure inside it is inseparable from the apparatus around it:

• Screening. Participants were selected against explicit eligibility criteria. People with particular comorbidities, particular laboratory values, particular medication histories and particular risk profiles were excluded before anything was administered. A reader searching for a dosing guide has passed through no such filter and has no way of knowing whether they would have.
• A defined, characterised drug product. Trial material is manufactured to pharmaceutical standards, at a known and verified strength, with documented identity and purity. The figure in the protocol refers to that product and nothing else.
• Supervision. An investigator is clinically and legally responsible for each participant. Adverse events are captured, graded and acted on by someone with the authority and obligation to intervene.
• Structured monitoring. Scheduled visits, defined laboratory work, defined stopping rules.
• Defined endpoints. The protocol is built to answer a specific pre-registered question. It was never designed as a set of instructions for use outside the study.

Lift a figure out of that and you keep the one component that is useless on its own. The screening, the supervision, the monitoring, the characterised product, the accountability - those are what make the figure interpretable, and none of them travel with it. What arrives at the reader is a number wearing the reputation of a trial it is no longer part of.

That is why we decline to republish it. Not because the information is secret - it is not - but because the act of republishing it strips away everything that gave it meaning and hands over the residue.

The concentration problem

There is a second failure, and it sits underneath the first.

A dose is a statement about quantity. A quantity is only meaningful if you know the concentration of what you are measuring from, and the concentration is only knowable if the material has been genuinely characterised by someone with no stake in the answer. In the approved-drug supply chain, that assurance comes from inspected manufacturing, batch release testing and regulatory oversight. Outside that chain, it is asserted rather than assured - and assertions can be forged.

On 3 August 2026, the owner of a US peptide seller was sentenced to 70 months in federal prison after pleading guilty to selling unapproved drugs and to illegal importation. He admitted forging laboratory certificates of analysis. Government testing of six products marketed as testosterone-mimetics found that all six contained actual testosterone. The business had served roughly 54,000 customers across 50 states and 80 countries.

The relevant detail is not the sentence length. It is the forged certificates. The certificate of analysis is precisely the document that a buyer relies on to know what is in a vial. When that document can be manufactured as easily as the label on the box, the entire chain of reasoning that turns a figure into a dose collapses at its first link. Precision about material of unverified identity and unverified strength is not precision. It is false precision, and it is more dangerous than open uncertainty, because it feels like control.

This is also why compounded and research-grade material cannot be treated as interchangeable with an approved product. Compounded preparations are not the approved product and do not carry the approved product's labelling, its manufacturing controls, or its regulatory accountability - a distinction we set out in is compounded GLP-1 legal. For retatrutide the point is sharper still: there is no approved product for anything to be compared against. Readers who want to understand how verification is supposed to work, rather than how it is claimed to work, will find that in how to assess a peptide source.

What regulators have actually said

This is not an area where the agencies have been silent or ambiguous.

On 31 March 2026, FDA's Center for Drug Evaluation and Research issued a warning letter to an online peptide seller (MARCS-CMS 721806) covering retatrutide and tirzepatide specifically. The letter is worth understanding for one legal reason in particular.

The products carried "Research Use Only" and "not intended for human consumption" statements on their labelling. FDA did not accept those statements as determinative. Under the intended-use doctrine codified at 21 CFR 201.128, a product's intended use is established by the objective circumstances surrounding its distribution - how it is marketed, what claims are made, who the audience plainly is, what the seller knows about how it will be used - not solely by a disclaimer printed on a container. On that basis the agency established that the products were intended as drugs for human use, and were therefore unapproved new drugs.

That letter was not isolated. FDA sent seven such letters to online peptide sellers in April 2026.

For a reader, the practical takeaway is not about any particular seller. It is that the "research use only" framing, which appears everywhere in this market and is often read as a legal shield for both parties, is not treated by the regulator as one. The broader legal picture is covered in are peptides legal in 2026.

Where retatrutide genuinely stands

Everything above is about documents. This section is about the drug, and it is more interesting than the guides suggest.

Mechanism. Retatrutide is an investigational triple agonist acting at the GIP, GLP-1 and glucagon receptors. The glucagon-receptor arm is what distinguishes it from the dual GIP/GLP-1 agents; it introduces an energy-expenditure component alongside the appetite and gastric-emptying effects familiar from the rest of the class. If that mechanistic vocabulary is unfamiliar, how GLP-1 agonists work is the place to start, and the retatrutide overview covers the compound in full.

Phase 3 results. TRIUMPH-2 and TRIUMPH-3 both met their primary endpoints. Both ran to an 80-week endpoint, with average weight loss reported in the range of roughly 20.8% to 22.6%. Those are published trial endpoints reported at the population level. They describe what happened to trial cohorts under trial conditions; they are not a promise, and they are not transferable to any individual.

The head-to-head has not reported. TRIUMPH-5 (NCT06662383) is the first randomised head-to-head comparison against tirzepatide. It is listed as active and not recruiting, and it has not reported. The earliest expected readouts are 2027 or later. Any comparative claim about investigational retatrutide versus tirzepatide circulating today is therefore an extrapolation across separate trials with different populations, not a head-to-head result - a distinction that matters, and which the tirzepatide long-term evidence review puts in context.

Regulatory timeline. Lilly plans to submit a Biologics License Application in Q1 2027, pushed back from an earlier expectation of end-2026 because additional manufacturing and quality-control data were required. The initial indications sought are obesity, obstructive sleep apnoea, and knee osteoarthritis pain. A planned submission is not an approval, and a submission date says nothing about whether, when, or with what labelling a regulator will ultimately act.

An unresolved dispute about the pathway itself. There is an active legal dispute with FDA over whether retatrutide is properly regulated as a biologic - requiring a BLA, with 12-year reference-product exclusivity - or as a drug, requiring an NDA, with 5 years. An initial court ruling was mixed and the litigation continues. That is an unusual situation: the question of which kind of application governs the product is itself being contested while the application is being prepared.

Access is narrow. Expanded-access arrangements exist for investigational products in defined circumstances, and they are considerably narrower than the way they are described online. The expanded-access explainer sets out what actually qualifies. Tolerability findings from the programme are covered in retatrutide side effects.

What would change this answer, and roughly when

The answer on this page changes when a regulator approves the product and a label is published. Not before.

The earliest plausible sequence runs through a BLA submission in Q1 2027, followed by a review period, followed - if the review is favourable - by an approval carrying an approved label with an approved dosing section. Each of those steps can slip, and the unresolved BLA-versus-NDA dispute adds a layer of uncertainty that most drug programmes do not have. Approval is not guaranteed at any point in that chain.

On the day an approved label exists, we will publish what it says, attributed to it, with the indication and population it was approved for stated alongside. That is not a hedge. It is the only condition under which publishing a dose is an act of information rather than an act of invention.

Until then, the honest answer to "is there a retatrutide dosing guide?" is that there is a great deal of material presenting itself as one, and nothing underneath it.

Frequently asked questions

Is retatrutide approved anywhere? It is not FDA-approved for any indication, and no approved label exists. Lilly plans to file a Biologics License Application in Q1 2027, with obesity, obstructive sleep apnoea and knee osteoarthritis pain as the initial indications sought. A planned filing is a statement of intent by a manufacturer, not a regulatory decision. Claims that the compound is approved somewhere else should be treated as requiring a citation to an actual regulator's decision document, and that citation is generally not produced when asked for.

Why do the online guides all show numbers? Because a number is what the reader arrived looking for, and a page that gives it will hold attention better than a page that explains why it cannot be given. Most such pages exist to sell something, or to sit adjacent to something being sold. The figures they display are typically paraphrased from trial protocols or reproduced from other pages that did the same, at which point provenance is lost entirely. The presence of a confident table is not evidence of a source behind it.

Isn't the trial dose public information? It is - and that is exactly the point. Trial protocols are published documents, and we are not treating them as secret. What we are declining to do is republish a figure in isolation. In a protocol, a figure is inseparable from the screening that selected the participants, the supervision that watched them, the monitoring that caught problems, the defined endpoints it was chosen to test, and the characterised drug product it refers to. Republishing it strips all of that away and hands over the one component that is useless alone. The number is not the valuable part of a protocol; the apparatus around it is.

When will there be an approved dose? Not before an approval, and possibly never - most investigational drugs do not reach approval, though retatrutide's Phase 3 results place it in a much stronger position than most. The earliest realistic path is a Q1 2027 submission, a review period, and a decision after that. The unresolved dispute over whether the product is reviewed as a biologic or as a drug adds further uncertainty to the timing. Anyone offering a firm date is guessing.

Related reading

• Retatrutide: the overview - mechanism, programme and current status in full
• The retatrutide evidence review - what the trial programme actually reports
• Retatrutide expanded access - how narrow the legitimate routes really are
• Retatrutide side effects - tolerability findings from the programme
• Is compounded GLP-1 legal? - why a compounded preparation is not the approved product
• Are peptides legal in 2026? - the regulatory picture around this market
• How to assess a peptide source - what verification means when a certificate can be forged
• What FDA accelerated approval means - reviewed is not the same as approved
• Why GLP-1 doses start low - the physiology that escalation schedules exist to accommodate

Part of GLP-1s.

Educational content, not medical advice. This article contains no doses, schedules, protocols or sourcing information, and nothing in it is a recommendation to start, stop, alter or continue any medication or to obtain any substance. Retatrutide is investigational and is not FDA-approved for any indication. Compounded and research-grade preparations are not the approved product and do not carry an approved product's labelling. Decisions about any medication belong to the clinician who prescribes it. Claims for the Malaysian market are subject to MAB requirements.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore retatrutide.

References

• US Department of Justice, sentencing announcement, 3 August 2026: owner of a US peptide seller sentenced to 70 months in federal prison after guilty pleas to selling unapproved drugs and illegal importation; admitted forging laboratory certificates of analysis. Government testing of six products marketed as testosterone-mimetics found all six contained testosterone; approximately 54,000 customers across 50 states and 80 countries. (Reported by CBS News.)
• US Food and Drug Administration, Center for Drug Evaluation and Research, warning letter to an online peptide seller, MARCS-CMS 721806, 31 March 2026 - covering retatrutide and tirzepatide; "Research Use Only" and "not intended for human consumption" statements did not preclude a finding of intended use as drugs for human use.
• 21 CFR 201.128 - intended use, as applied in the above.
• US Food and Drug Administration - series of seven warning letters issued to online peptide sellers, April 2026.
• Eli Lilly and Company - statements on the planned Biologics License Application for investigational retatrutide, submission planned for Q1 2027, revised from an earlier end-2026 expectation pending additional manufacturing and quality-control data; initial indications sought: obesity, obstructive sleep apnoea, knee osteoarthritis pain.
• TRIUMPH-2 and TRIUMPH-3 - Phase 3 trials of investigational retatrutide, both meeting primary endpoints; average weight loss reported in the range of approximately 20.8% to 22.6% at the 80-week endpoint.
• TRIUMPH-5 (NCT06662383) - randomised head-to-head comparison of investigational retatrutide versus tirzepatide; active, not recruiting; no results reported as of this review date, with earliest readouts expected 2027 or later.
• Ongoing litigation regarding the applicable regulatory pathway for retatrutide - biologic (BLA, 12-year reference-product exclusivity) versus drug (NDA, 5 years); initial ruling mixed, litigation continuing.